Close
4
FDA-DMF-Filings-in-2019
X

Overview of CAS 1314556-33-6

Client Email Product
4CH-023469
PharmaCompass
4CH-023469
Also known as: 864070-44-0, Jardiance, Bi 10773, Unii-hdc1r2m35u, Bi-10773, Bi10773
Molecular Formula
C23H27ClO7
Molecular Weight
450.912  g/mol
InChI Key
OBWASQILIWPZMG-QZMOQZSNSA-N
FDA UNII
HDC1R2M35U

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.
Empagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of empagliflozin is as a Sodium-Glucose Transporter 2 Inhibitor.
1 2D Structure

4CH-023469

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
2.1.2 InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
2.1.3 InChI Key
OBWASQILIWPZMG-QZMOQZSNSA-N
2.1.4 Canonical SMILES
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
2.1.5 Isomeric SMILES
C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
2.2 Other Identifiers
2.2.1 UNII
HDC1R2M35U
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 864070-44-0

2. Jardiance

3. Bi 10773

4. Unii-hdc1r2m35u

5. Bi-10773

6. Bi10773

7. Hdc1r2m35u

8. Chebi:82720

9. 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene

10. Ak160980

11. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(((s)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

12. Empagliflozin (bi 10773)

13. (1s)-1,5-anhydro-1-(4-chloro-3-{4-[(3s)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-d-glucitol

14. (1s)-1,5-anhydro-1-c-{4-chloro-3-((4-{((3s)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-d-glucitol

15. Empagliflozin [usan:inn]

16. Jardiance (tn)

17. Tube106

18. (s)-empagliflozin D4

19. Empagliflozin/linagliptin

20. D06ald

21. D0p7pd

22. Bi-10773;empagliflozin

23. Empagliflozin (bi10773)

24. C23h27clo7

25. Schembl899986

26. Gtpl4754

27. Chembl2107830

28. Empagliflozin (jan/usan/inn)

29. Ex-a414

30. Molport-027-720-828

31. Bdbm150162

32. Ce0108

33. Mfcd22566222

34. S8022

35. Us8980829, Empagliflozin

36. Zinc36520252

37. Akos024464680

38. Cs-0940

39. Db09038

40. Ds-9824

41. Pb23119

42. Va10802

43. Ks-0000072w

44. Ac-27643

45. Aj-93046

46. Bc600492

47. Hy-15409

48. Kb-76792

49. Sc-15843

50. Ax8293990

51. 4ch-023469

52. St24046679

53. X5927

54. D10459

55. Q-4526

56. Empagliflozin (bi-10773;bi 10773;bi10773)

57. (1s)-1,5-anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-d-glucitol

58. (2s,3r,4r,5s,6r)-2-[4-chloro-3-({4-[(3s)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

59. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

60. 1314556-33-6

2.4 Create Date
2006-11-20
3 Chemical and Physical Properties
Molecular Weight 450.912 g/mol
Molecular Formula C23H27ClO7
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass450.145 g/mol
Monoisotopic Mass450.145 g/mol
Topological Polar Surface Area109 A^2
Heavy Atom Count31
Formal Charge0
Complexity558
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameJARDIANCE
Active IngredientEMPAGLIFLOZIN
CompanyBOEHRINGER INGELHEIM (Application Number: N204629. Patents: 7579449, 7713938, 8551957)

2 of 4  
Drug NameGLYXAMBI
Active IngredientEMPAGLIFLOZIN; LINAGLIPTIN
CompanyBOEHRINGER INGELHEIM (Application Number: N206073. Patents: 6890898, 7078381, 7407955, 7459428, 7579449, 7713938, 8119648, 8178541, 8551957, 8673927, 8883805, 9173859)

3 of 4  
Drug NameSYNJARDY XR
Active IngredientEMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
CompanyBOEHRINGER INGELHEIM (Application Number: N208658. Patents: 6488962, 7579449, 7713938)

4 of 4  
Drug NameSYNJARDY
Active IngredientEMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
CompanyBOEHRINGER INGELHEIM (Application Number: N206111. Patents: 7579449, 7713938)

4.2 Drug Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.


FDA Label


Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes
For study results with respect to combinations, effects on glycaemic control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1 of the SmPC.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Hypoglycemic Agents

Substances which lower blood glucose levels.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety

EMPAGLIFLOZIN


5.2.2 FDA UNII

HDC1R2M35U


5.2.3 Pharmacological Classes

Established Pharmacologic Class [EPC]

Sodium-Glucose Cotransporter 2 Inhibitor


Mechanisms of Action [MoA]

Sodium-Glucose Transporter 2 Inhibitors


5.3 ATC Code

Anatomical main group: A - Alimentary tract and metabolism
Therapeutic subgroup: A10 - Drugs used in diabetes
Pharmacological subgroup: A10B - Blood glucose lowering drugs, excluding insulins
Chemical subgroup: A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Chemical substance: A10BK03 - empagliflozin


A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
A10BK03 - Empagliflozin


5.4 Absorption, Distribution and Excretion

Absorption

Following oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition.


Route of Elimination

After oral administration, empaglifozin was 41.2% eliminated in feces and 54.4% eliminated in urine.


Volume of Distribution

73.8 L


Clearance

Apparent oral clearance was found to be 10.6 L/h based on population pharmacokinetic analysis.


5.5 Metabolism/Metabolites

Metabolism

In vitro studies suggest that empaglifozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates.


5.6 Biological Half-Life

Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.


5.7 Mechanism of Action

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty

Advertise With Us

Advertise With Us